CLAIMS

1. Use of a combination comprising Cyclophosphamide, Vincristine, Prednisone and Pralatrexate, in the manufacture of a medicament for treating peripheral T-cell lymphoma (PTCL) in a subject in need thereof, and wherein the combination does not comprise doxorubicin.

2. The use according to claim 1, wherein the combination consists of Cyclophosphamide, Vincristine, Prednisone and Pralatrexate.

3. The use according to claim 1 or 2, wherein the combination is to be administered in a three-week cycle optionally comprising a drug holiday.

4. The use according to claim 3, wherein the Cyclophosphamide, Vincristine, Prednisone and Pralatrexate are to be independently administered daily, weekly, or once every two weeks for at most two weeks of the three-week cycle, such that the three-week cycle contains a weeklong drug holiday.

5. The use according to claim 3 or 4, wherein the three-week cycle is repeated from at least 1 to 10 times.

6. The use according to claim 5, wherein the three-week cycle is repeated one time, two times, three times, four times, five times, six times, seven times, eight times, nine times, or ten times.

7. The use according to any one of claims 1-6, wherein the Pralatextrate is to be administered on days 1 and 8 of a treatment cycle.

8. The use according to any one of claims 1-6, wherein the Cyclophosphamide and/or Vinicristine, and/or Predinisone is to be administered daily for a time period within the treatment cycle.

9. The use according to any one of claims 1-6 , wherein the Cyclophosphamide and/or Vinicristine, and/or Predinisone is to be Eadministered daily for days 1-15, or for days 1-10, or for days 1-8, or for days 1-6, or for days 1-5, or for days 1-4, or for days 1-3 of the treatment cycle.

10. The use of claim 1, wherein the administration comprises a 21 day treatment cycle, the treatment cycle comprising:

a) administering Pralatrexate in a dosage of at least about 10 mg/m^2 intravenously on day 1 and day 8;

b) administering Cyclophosphamide in a dosage of at least about 700 mg/m^2 intravenously and Vincristine in a dosage of at least about 1 mg/m^2 intravenously, on day 1,

wherein the Cyclophosphamide and/or Vinicristine are independently optionally administered following or concomitantly with the administration of Pralatrexate on day 1; and

c) administering Prednisone in a dosage of at least about 50 mg orally on each of day 1 to day 5, wherein the prednisone is optionally administered on day 1 following the administration of Pralatrexate.

11. The use of claim 10, wherein the 21 day cycle is repeated between 1 to 6 times.

12. The use of claim 10 or 11, wherein the treatment cycle comprises at least one of:

a) administering Pralatrexate in a dosage of about 20 to about 30 mg/m^2 intravenously on day 1 and day 8;

b1) administering Cyclophosphamide in a dosage of from about 700 mg/m^2 to about 800 mg/m^2 on day 1;

b2) administering Cyclophosphamide in a dosage of about 750 mg/ m^2 intravenously on day 1;

b3) administering Vincristine in a dosage of from about 1 mg/m^2 to about 2 mg/m^2 intravenously on day 1,

b4) administering Vinicristine in a dosage of about 1.2 mg/m^2 to about 1.6 mg/m^2 intravenously on day 1,

b5) administering Vinicristine in a dosage of about 1.4 mg/m^2, intravenously, on day 1,

c1) administering Prednisone in a dosage of from about 50 mg to 150 mg on day 1 following administration of Pralatrexate;

c2) administering Prednisone in a dosage of from about 80 mg to about 120 mg on day 1 following administration of Pralatrexate, and

c3) administering Prednisone in a dosage of about 100 mg orally on day 1 following administration of Pralatrexate.

13. A kit comprising Pralatrexate, Cyclophosphamide, Vincristine, and Prednisone, wherein said kit does not comprise doxorubicin.

14. The kit of claim 13, wherein the Pralatrexate, is formulated separately from the Cyclophosphamide, the Vincristine, and the Prednisone.

15. The kit of claim 13, wherein the kit comprises a first pharmaceutical composition comprising about 20 to 30 mg/m^2 Pralatrexate and a first pharmaceutically acceptable excipient and/or a second pharmaceutical composition comprising about 500-1000 mg/m^2 Cyclophosphamide and a second pharmaceutically acceptable excipient, and/or a third pharmaceutical composition comprising about 1-3 mg/m^2 Vinicristine and a third pharmaceutically acceptable excipient, and/or a fourth pharmaceutical composition comprising about 50-150 mg Prednisone and a fourth pharmaceutically acceptable excipient.

16. The kit according to claim 15, wherein at least two of the first pharmaceutical composition, second pharmaceutical composition, third pharmaceutical composition and fourth pharmaceutical composition are the same pharmaceutical composition.

17. The kit of claim 15 or 16, wherein the first pharmaceutical composition is an intravenous composition.

18. The kit of any one of claims 15-17, wherein the second pharmaceutical composition is an intravenous composition.

19. The kit of any one of claims 15-18, wherein the third pharmaceutical composition is an intravenous composition.

20. The kit of any one of claims 15-19, wherein the fourth pharmaceutical composition is an oral composition.

21. The kit of any one of claims 15-20, wherein the second composition comprises about 700-800 mg/m^2 Cyclophosphamide.

22. The kit of any one of claims 15-20, wherein the second composition comprises about 750 mg/m^2 Cyclophosphamide.

23. The kit of any one of claims 15-22, wherein the third composition comprises about 1-2 mg/m^2 Vinicristine.

24. The kit of any one of claims 15-22, wherein the third composition comprises about 1.2-1.6 mg/m^2 Vinicristine.

25. The kit of any one of claims 15-22, wherein the third composition comprises about 1.4 mg/m^2 Vincristine.

26. The kit of any one of claims 15-25, wherein the fourth composition comprises about 75-125 mg Prednisone.

27. The kit of any one of claims 15-25, wherein the fourth composition comprises about 100 mg Prednisone.